First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
Guangdong General Hospital · Guangdong Academy of Medical Sciences · +19 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
733
total citations
- FWCI
- 52.23
- Percentile
- 100%
- References
- 18
Citations per year
Authors
22Topics & keywords
Topics
Keywords
- Erlotinib
- Medicine
- Gemcitabine
- Internal medicine
- Erlotinib Hydrochloride
- Hazard ratio
- Lung cancer
- Epidermal growth factor receptor
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.